Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07127822 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Start date changed from estimate of Sep 1, 2025 to Dec 15, 2025
    • Trial sites expanded: 1 → 10 locations
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomized controlled phase II study exploring first-line treatment options for recurrent/metastatic MSI-H gastric cancer
Trial Details
NCT Number NCT07127822
Lead Sponsor Peking University
Collaborators: Peking University Cancer Hospital & Institute, Qilu Pharmaceutical Group Co., Ltd
Conditions
(from sponsor)		 Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
Enrollment 106 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov